Trex sale speculation causes corporate earnings to slump

Article

Company won't name potential suitors Trex Medical president and CEO William Webb blamed his company's low second quarter 2000 earnings on uncertainty among customers and dealers while his company is up for sale. Trex Medical's revenue for the

Company won't name potential suitors

Trex Medical president and CEO William Webb blamed his company's low second quarter 2000 earnings on uncertainty among customers and dealers while his company is up for sale.

Trex Medical's revenue for the quarter (end April 1) was $41.4 million, compared to $60.2 million for the quarter in 1999. Net loss for the quarter was $6.6 million, compared to a net loss of $ 4.2 million for the same quarter last year.

The company spent $900,000 on restructuring costs this year, compared with $600,000 last year.

Trex has not been performing well since parent company Thermo Electron, which makes measurement instruments, announced it would seek a buyer for its subsidiary earlier this year.

Adding to its woes, the company lost a breast biopsy table distribution contract with U.S. Surgical and many top executives have left. Trex was expected to be the first U.S. company to receive 510(k) approval for its full-field digital mammography unit, but GE Medical beat it out in the race. Webb has said he hopes Trex can find a buyer in the diagnostic imaging field (SCAN 2/16/00).

Speculation about who will buy Trex abounds in the industry. Caroline Grossman, Thermo Electron spokesperson, said Trex officials would not comment on the sale or elaborate on Trex's second quarter results.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.